ORs and 95% CIs for diabetic peripheral neuropathy
| . | Unadjusted . | Multivariate adjusted* . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P . | OR (95% CI) . | P . |
| CAVIa | 1.37 (1.20–1.56) | <0.001 | 1.36 (1.13–1.65) | 0.001 |
| Age (years) | 1.02 (1.01–1.04) | 0.010 | 0.98 (0.95–1.01) | 0.110 |
| Male sex | 1.25 (0.86–1.84) | 0.247 | 0.57 (0.35–0.93) | 0.024 |
| Duration (years) | 1.05 (1.02–1.07) | <0.001 | 1.04 (1.01–1.07) | 0.005 |
| BMI (kg/m2) | 0.92 (0.87–0.98) | 0.010 | 0.96 (0.90–1.04) | 0.323 |
| HbA1c (%) | 1.00 (0.91–1.11) | 0.936 | 0.98 (0.86–1.11) | 0.691 |
| Pulse pressure (mmHg) | 1.02 (1.00–1.03) | 0.021 | 1.01 (0.99–1.03) | 0.388 |
| GFR (mL/min per 1.73 m2) | 0.99 (0.98–1.00) | 0.012 | 1.00 (0.99–1.01) | 0.533 |
| Hyperlipidemiab | 0.96 (0.59–1.57) | 0.884 | 1.01 (0.57–1.79) | 0.964 |
| CVD | 1.83 (1.01–3.31) | 0.045 | 2.09 (1.01–4.32) | 0.048 |
| Autonomic neuropathy | 1.26 (0.80–2.00) | 0.324 | 0.89 (0.51–1.54) | 0.575 |
| Current smokers | 1.05 (0.43–2.60) | 0.912 | 1.34 (0.48–3.74) | 0.679 |
| Insulin therapy | 1.32 (0.90–1.94) | 0.161 | 1.05 (0.62–1.77) | 0.856 |
| ACE inhibitor/ARB | 0.76 (0.51–1.12) | 0.163 | 0.63 (0.38–1.03) | 0.067 |
| Calcium channel blocker | 0.80 (0.49–1.29) | 0.628 | 0.81 (0.45–1.47) | 0.489 |
| β-Blocker | 0.85 (0.45–1.63) | 0.624 | 0.86 (0.39–1.88) | 0.701 |
| . | Unadjusted . | Multivariate adjusted* . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P . | OR (95% CI) . | P . |
| CAVIa | 1.37 (1.20–1.56) | <0.001 | 1.36 (1.13–1.65) | 0.001 |
| Age (years) | 1.02 (1.01–1.04) | 0.010 | 0.98 (0.95–1.01) | 0.110 |
| Male sex | 1.25 (0.86–1.84) | 0.247 | 0.57 (0.35–0.93) | 0.024 |
| Duration (years) | 1.05 (1.02–1.07) | <0.001 | 1.04 (1.01–1.07) | 0.005 |
| BMI (kg/m2) | 0.92 (0.87–0.98) | 0.010 | 0.96 (0.90–1.04) | 0.323 |
| HbA1c (%) | 1.00 (0.91–1.11) | 0.936 | 0.98 (0.86–1.11) | 0.691 |
| Pulse pressure (mmHg) | 1.02 (1.00–1.03) | 0.021 | 1.01 (0.99–1.03) | 0.388 |
| GFR (mL/min per 1.73 m2) | 0.99 (0.98–1.00) | 0.012 | 1.00 (0.99–1.01) | 0.533 |
| Hyperlipidemiab | 0.96 (0.59–1.57) | 0.884 | 1.01 (0.57–1.79) | 0.964 |
| CVD | 1.83 (1.01–3.31) | 0.045 | 2.09 (1.01–4.32) | 0.048 |
| Autonomic neuropathy | 1.26 (0.80–2.00) | 0.324 | 0.89 (0.51–1.54) | 0.575 |
| Current smokers | 1.05 (0.43–2.60) | 0.912 | 1.34 (0.48–3.74) | 0.679 |
| Insulin therapy | 1.32 (0.90–1.94) | 0.161 | 1.05 (0.62–1.77) | 0.856 |
| ACE inhibitor/ARB | 0.76 (0.51–1.12) | 0.163 | 0.63 (0.38–1.03) | 0.067 |
| Calcium channel blocker | 0.80 (0.49–1.29) | 0.628 | 0.81 (0.45–1.47) | 0.489 |
| β-Blocker | 0.85 (0.45–1.63) | 0.624 | 0.86 (0.39–1.88) | 0.701 |
ARB, angiotensin II receptor blocker; GFR, glomerular filtration rate.
aCAVI is a continuous measure.
bHyperlipidemia was defined as a triglyceride concentration ≥150 mg/dL, low-density lipoprotein concentration ≥100 mg/dL, or taking cholesterol-lowering medication.
*Adjusted for all other variables in the first column.